Children aged 8–12 treated for over two years with NaturalVue Multifocal contact lenses (Visioneering Technologies, Inc), had significantly lower myopia progression versus single-vision contact lenses, according to new analyses from the ongoing PROTECT randomised clinical trial.
‘PROTECT’ (PROgressive Myopia Treatment Evaluation for NaturalVue Multifocal Contact Lens Trial) is a three-year, prospective, double-masked multi-national trial evaluating the safety and effectiveness of NaturalVue Multifocal contact lenses for slowing myopia progression. The study involves 145 children with participating investigators in the United States, Canada, Hong Kong, and Singapore.
At the Global Specialty Lens Symposium, VTI’s Chief Medical Officer, Dr Ashley Tuan, reported that children fitted with NaturalVue Multifocal contact lenses for over two years had 0.59 D less refractive progression and 0.22 mm less axial elongation.1
Additionally, he reported:
- Machine-learning analyses identified age as the strongest driver of progression under natural history, while treatment with NaturalVue Multifocal reduced the overall impact of known risk factors by approximately 45–58%,
- Treatment effects were consistent across age, sex, pupil size, familial, and lifestyle variables, indicating age of initiation did not meaningfully alter efficacy, and
- Under natural progression, females demonstrated faster progression than males; this sex-based risk factor was minimised in children wearing NaturalVue Multifocal.1
Reference
- Tuan A, Novak S, Dillehay S, PROTECT Study Group. Clinical, familial, and social risk factors for myopia progression: learnings from the PROTECT 2-year data. Poster presented at Global Specialty Lens Symposia; 8 January 2026; Las Vegas, NV.
